Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies

作者: Yanina Sguassero , Cristina B. Cuesta , Karen N. Roberts , Elizabeth Hicks , Daniel Comandé

DOI: 10.1371/JOURNAL.PONE.0139363

关键词:

摘要: Background Chagas disease is caused by the flagellate protozoan Trypanosoma cruzi (T. cruzi). It endemic in Latin American countries outside Caribbean. The current criterion for cure chronic phase of negativization at least two serological tests such as enzyme-linked immunosorbent assay (ELISA), indirect immunofluorescence (IIF) and hemagglutination (IHA). evolution treated subjects with T. infection variable. Treatment failure indicated a positive parasitological and/or molecular test (persistence parasitemia). Objectives To summarize pattern response to treatment parasitological, performed during follow-up infection. Methods Electronic searches relevant databases screening citations potentially eligible articles were accomplished. Organizations focusing on neglected infectious diseases asked help identifying studies. Included studies randomized controlled trials (RCTs), quasi-RCTs, cohort involving adults children who received trypanocidal (benznidazole or nifurtimox) followed over time. assessment risk bias was separately each study design. Cochrane Collaboration’s tool guidelines developed Hayden et al. used. Two reviewers extracted all data independently. A third review author consulted case discordant opinion. Additional analyses defined ad-hoc basis. Scatter plots percentage negative using lowess curve technique. Heterogeneity measured I2. The protocol registered PROSPERO, an international prospective register systematic protocols (Registration Number CRD42012002162). Results Out 2,136 screened, 54 (six RCTs 48 studies) included. smoothed curves xenodiagnosis polymerase chain reaction (PCR) characterized sharp decrease twelve month posttreatment. Afterwards, they reached 10–20% 40% PCR, respectively. conventional increased up 10% after months treatment. In long-term, rate between 20% 45%. The main sources identified across lack control confounding attrition bias. general, judged low domains. level heterogeneity included moderate high. Additional analysis incomplete because limited availability data. this regard, country origin participants might affect results tests, while outcomes. Subgroup suggested that seronegativization occurs earlier compared adults. Conclusions We acknowledge there dynamic based chronically infected Our findings suggest effect long-term follow-up. Further research needed explore potential conduct reliable subgroup analysis.

参考文章(82)
R R Gallerano, R R Sosa, [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy]. Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina). ,vol. 57, pp. 135- 162 ,(2000)
Liliana Cervetta, Edgardo Moretti, Beatriz Basso, Irma Castro, Norberto Santamarina, Enfermedad de Chagas crónica: efectos del tratamiento en los niveles de anticuerpos hacia antígenos crudos y semipurificados del Trypanosoma cruzi Boletín chileno de parasitología. ,vol. 53, pp. 3- 9 ,(1998)
Ninfa Vera de Bilbao, Susana Torres, Liliana Sosa, Valentina Díaz, María Mercedes Carpinelli de Tomassone, J Martínez, Estela Elías, Evolución serológica y parasitológica post-tratamiento de pacientes con enfermedad de Chagas crónica reciente Memorias del Instituto de Investigaciones en Ciencias de la Salud. ,vol. 4, pp. 5- 10 ,(2006)
Myriam Lorca H, Maricarmen Contreras L, Hugo Schenone F, Antonio Rojas S, Aldo Solari I, Alejandro García C, Tratamiento con Nifurtimox de la infección chagásica crónica en niños Nifurtimox treatment of chronic Chagasic infection in children ,(2003)
Camila Aguiar, Angelica M. Batista, Tycha B. S. Pavan, Eros A. Almeida, Maria E. Guariento, Jamiro S. Wanderley, Sandra C. B. Costa, Serological profiles and evaluation of parasitaemia by PCR and blood culture in individuals chronically infected by Trypanosoma cruzi treated with benzonidazole. Tropical Medicine & International Health. ,vol. 17, pp. 368- 373 ,(2011) , 10.1111/J.1365-3156.2011.02936.X
Tanya Horsley, Orvie Dingwall, Margaret Sampson, Checking reference lists to find additional studies for systematic reviews Cochrane Database of Systematic Reviews. ,(2011) , 10.1002/14651858.MR000026.PUB2
A. Pérez-Ayala, J.A. Pérez-Molina, F. Norman, M. Navarro, B. Monge-Maillo, M. Díaz-Menéndez, J. Peris-García, M. Flores, C. Cañavate, R. López-Vélez, Chagas disease in Latin American migrants: a Spanish challenge Clinical Microbiology and Infection. ,vol. 17, pp. 1108- 1113 ,(2011) , 10.1111/J.1469-0691.2010.03423.X
Regina Ayr Florio da CUNHA, Kioko TAKEI, Adelaide José VAZ, Caio ROSENTHAL, Detection of mycoplasmas in urethral swabs from HIV-1 infected patients and control individuals using culture techniques and polymerase chain reaction Revista Do Instituto De Medicina Tropical De Sao Paulo. ,vol. 40, pp. 1- 5 ,(1998) , 10.1590/S0036-46651998000100001
Bianca Zingales, Michael A Miles, Carolina B Moraes, Alejandro Luquetti, Felipe Guhl, Alejandro G Schijman, Isabela Ribeiro, Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity Memorias Do Instituto Oswaldo Cruz. ,vol. 109, pp. 828- 833 ,(2014) , 10.1590/0074-0276140156